A Phase 2a trial evaluating AQST-108 (epinephrine) Topical Gel in patients with alopecia areata (AA)
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs AQST 108 (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- 20 Jan 2025 New trial record
- 13 Jan 2025 According to Aquestive Therapeutics media release company has successfully completed a pre-Investigational New Drug meeting with the FDA in December 2024 and remains on track to begin its Phase 2a trial in patients with alopecia areata (AA) in the second quarter of 2025.